Assembly and Misassembly of Cystic Fibrosis Transmembrane Conductance Regulator: Folding Defects Caused by Deletion of F508 Occur Before and After the Calnexin-dependent Association of Membrane Spanning Domain (MSD) 1 and MSD2

Overview

Journal Mol Biol Cell

Specialties Cell Biology
Molecular Biology

Date 2008 Aug 22

PMID 18716059

Citations 52

Authors

Meredith F N Rosser

Diane E Grove

Liling Chen

Douglas M Cyr

Affiliations

Soon will be listed here.

Abstract

Cystic fibrosis transmembrane conductance regulator (CFTR) is a polytopic membrane protein that functions as a Cl(-) channel and consists of two membrane spanning domains (MSDs), two cytosolic nucleotide binding domains (NBDs), and a cytosolic regulatory domain. Cytosolic 70-kDa heat shock protein (Hsp70), and endoplasmic reticulum-localized calnexin are chaperones that facilitate CFTR biogenesis. Hsp70 functions in both the cotranslational folding and posttranslational degradation of CFTR. Yet, the mechanism for calnexin action in folding and quality control of CFTR is not clear. Investigation of this question revealed that calnexin is not essential for CFTR or CFTRDeltaF508 degradation. We identified a dependence on calnexin for proper assembly of CFTR's membrane spanning domains. Interestingly, efficient folding of NBD2 was also found to be dependent upon calnexin binding to CFTR. Furthermore, we identified folding defects caused by deletion of F508 that occurred before and after the calnexin-dependent association of MSD1 and MSD2. Early folding defects are evident upon translation of the NBD1 and R-domain and are sensed by the RMA-1 ubiquitin ligase complex.

Citing Articles

Proteostasis Landscapes of Cystic Fibrosis Variants Reveals Drug Response Vulnerability.

McDonald E, Kim M, Olson J, Olson 3rd J, Meiler J, Plate L bioRxiv. 2024; .

PMID: 39026768 PMC: 11257600. DOI: 10.1101/2024.07.10.602964.

Unity Is Strength: The Mutual Alliance between CFTR and SLC26A6 as Therapeutic Opportunity in Cystic Fibrosis.

Pariano M, Antognelli C, Romani L, Costantini C Pharmaceuticals (Basel). 2024; 17(3).

PMID: 38543153 PMC: 10974424. DOI: 10.3390/ph17030367.

A uniquely efficacious type of CFTR corrector with complementary mode of action.

Marchesin V, Monnier L, Blattmann P, Chevillard F, Kuntz C, Forny C Sci Adv. 2024; 10(9):eadk1814.

PMID: 38427726 PMC: 11801377. DOI: 10.1126/sciadv.adk1814.

Transmembrane Helices 7 and 8 Confer Aggregation Sensitivity to the Cystic Fibrosis Transmembrane Conductance Regulator.

Kleizen B, de Mattos E, Papaioannou O, Monti M, Tartaglia G, van der Sluijs P Int J Mol Sci. 2023; 24(21).

PMID: 37958724 PMC: 10648718. DOI: 10.3390/ijms242115741.

Folding correctors can restore CFTR posttranslational folding landscape by allosteric domain-domain coupling.

Soya N, Xu H, Roldan A, Yang Z, Ye H, Jiang F Nat Commun. 2023; 14(1):6868.

PMID: 37891162 PMC: 10611759. DOI: 10.1038/s41467-023-42586-8.

References

Riordan J, Rommens J, Kerem B, Alon N, Rozmahel R, Grzelczak Z . Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science. 1989; 245(4922):1066-73. DOI: 10.1126/science.2475911. View

Serohijos A, Hegedus T, Aleksandrov A, He L, Cui L, Dokholyan N . Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. Proc Natl Acad Sci U S A. 2008; 105(9):3256-61. PMC: 2265173. DOI: 10.1073/pnas.0800254105. View

MEACHAM G, Patterson C, Zhang W, Younger J, Cyr D . The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol. 2001; 3(1):100-5. DOI: 10.1038/35050509. View

Farinha C, Amaral M . Most F508del-CFTR is targeted to degradation at an early folding checkpoint and independently of calnexin. Mol Cell Biol. 2005; 25(12):5242-52. PMC: 1140594. DOI: 10.1128/MCB.25.12.5242-5252.2005. View

Zhang F, Kartner N, Lukacs G . Limited proteolysis as a probe for arrested conformational maturation of delta F508 CFTR. Nat Struct Biol. 1998; 5(3):180-3. DOI: 10.1038/nsb0398-180. View

Wang X, Venable J, LaPointe P, Hutt D, Koulov A, Coppinger J . Hsp90 cochaperone Aha1 downregulation rescues misfolding of CFTR in cystic fibrosis. Cell. 2006; 127(4):803-15. DOI: 10.1016/j.cell.2006.09.043. View

Chen E, Bartlett M, Loo T, Clarke D . The DeltaF508 mutation disrupts packing of the transmembrane segments of the cystic fibrosis transmembrane conductance regulator. J Biol Chem. 2004; 279(38):39620-7. DOI: 10.1074/jbc.M407887200. View

Okiyoneda T, Niibori A, Harada K, Kohno T, Michalak M, Duszyk M . Role of calnexin in the ER quality control and productive folding of CFTR; differential effect of calnexin knockout on wild-type and DeltaF508 CFTR. Biochim Biophys Acta. 2008; 1783(9):1585-94. DOI: 10.1016/j.bbamcr.2008.04.002. View

Hammond C, Braakman I, Helenius A . Role of N-linked oligosaccharide recognition, glucose trimming, and calnexin in glycoprotein folding and quality control. Proc Natl Acad Sci U S A. 1994; 91(3):913-7. PMC: 521423. DOI: 10.1073/pnas.91.3.913. View

10.

Cui L, Aleksandrov L, Chang X, Hou Y, He L, Hegedus T . Domain interdependence in the biosynthetic assembly of CFTR. J Mol Biol. 2006; 365(4):981-94. DOI: 10.1016/j.jmb.2006.10.086. View

11.

Skach W . Defects in processing and trafficking of the cystic fibrosis transmembrane conductance regulator. Kidney Int. 2000; 57(3):825-31. DOI: 10.1046/j.1523-1755.2000.00921.x. View

12.

Lewis H, Buchanan S, Burley S, Conners K, Dickey M, Dorwart M . Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator. EMBO J. 2003; 23(2):282-93. PMC: 1271750. DOI: 10.1038/sj.emboj.7600040. View

13.

Xiong X, Bragin A, Widdicombe J, Cohn J, Skach W . Structural cues involved in endoplasmic reticulum degradation of G85E and G91R mutant cystic fibrosis transmembrane conductance regulator. J Clin Invest. 1997; 100(5):1079-88. PMC: 508282. DOI: 10.1172/JCI119618. View

14.

Kopito R . Biosynthesis and degradation of CFTR. Physiol Rev. 1999; 79(1 Suppl):S167-73. DOI: 10.1152/physrev.1999.79.1.S167. View

15.

Mendoza J, Thomas P . Building an understanding of cystic fibrosis on the foundation of ABC transporter structures. J Bioenerg Biomembr. 2007; 39(5-6):499-505. DOI: 10.1007/s10863-007-9117-7. View

16.

Chan K, Csanady L, Seto-Young D, Nairn A, Gadsby D . Severed molecules functionally define the boundaries of the cystic fibrosis transmembrane conductance regulator's NH(2)-terminal nucleotide binding domain. J Gen Physiol. 2000; 116(2):163-80. PMC: 2229491. DOI: 10.1085/jgp.116.2.163. View

17.

Dawson R, Locher K . Structure of a bacterial multidrug ABC transporter. Nature. 2006; 443(7108):180-5. DOI: 10.1038/nature05155. View

18.

Okiyoneda T, Harada K, Takeya M, Yamahira K, Wada I, Shuto T . Delta F508 CFTR pool in the endoplasmic reticulum is increased by calnexin overexpression. Mol Biol Cell. 2003; 15(2):563-74. PMC: 329241. DOI: 10.1091/mbc.e03-06-0379. View

19.

Cheng S, Gregory R, Marshall J, Paul S, Souza D, White G . Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. Cell. 1990; 63(4):827-34. DOI: 10.1016/0092-8674(90)90148-8. View

20.

Ostedgaard L, Rich D, DeBerg L, Welsh M . Association of domains within the cystic fibrosis transmembrane conductance regulator. Biochemistry. 1997; 36(6):1287-94. DOI: 10.1021/bi962174s. View